These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 20712010)
1. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites. Mitselou A; Batistatou A; Nakanishi Y; Hirohashi S; Vougiouklakis T; Charalabopoulos K Histol Histopathol; 2010 Oct; 25(10):1257-67. PubMed ID: 20712010 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer. Tamura M; Ohta Y; Tsunezuka Y; Matsumoto I; Kawakami K; Oda M; Watanabe G J Thorac Cardiovasc Surg; 2005 Sep; 130(3):740-5. PubMed ID: 16153922 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Shimada Y; Hashimoto Y; Kan T; Kawamura J; Okumura T; Soma T; Kondo K; Teratani N; Watanabe G; Ino Y; Sakamoto M; Hirohashi S; Imamura M Oncology; 2004; 67(1):73-80. PubMed ID: 15459499 [TBL] [Abstract][Full Text] [Related]
4. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression. Shimamura T; Sakamoto M; Ino Y; Sato Y; Shimada K; Kosuge T; Sekihara H; Hirohashi S J Clin Oncol; 2003 Feb; 21(4):659-67. PubMed ID: 12586803 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases. Nakanishi Y; Akimoto S; Sato Y; Kanai Y; Sakamoto M; Hirohashi S Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):323-8. PubMed ID: 15536331 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer. Choi YS; Shim YM; Kim SH; Son DS; Lee HS; Kim GY; Han J; Kim J Eur J Cardiothorac Surg; 2003 Sep; 24(3):441-9. PubMed ID: 12965318 [TBL] [Abstract][Full Text] [Related]
7. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. Batistatou A; Peschos D; Tsanou H; Charalabopoulos A; Nakanishi Y; Hirohashi S; Agnantis NJ; Charalabopoulos K Br J Cancer; 2007 May; 96(9):1404-8. PubMed ID: 17437014 [TBL] [Abstract][Full Text] [Related]
8. Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC. Ono K; Uramoto H; Hanagiri T Anticancer Res; 2010 Sep; 30(9):3273-8. PubMed ID: 20944097 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of dysadherin expression in advanced colorectal carcinoma. Aoki S; Shimamura T; Shibata T; Nakanishi Y; Moriya Y; Sato Y; Kitajima M; Sakamoto M; Hirohashi S Br J Cancer; 2003 Mar; 88(5):726-32. PubMed ID: 12618882 [TBL] [Abstract][Full Text] [Related]
10. Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. Batistatou A; Charalabopoulos AK; Scopa CD; Nakanishi Y; Kappas A; Hirohashi S; Agnantis NJ; Charalabopoulos K Virchows Arch; 2006 Jun; 448(6):763-7. PubMed ID: 16570180 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of dysadherin and E-cadherin expression in patients with head and neck cancer treated by radiation therapy. Muramatsu H; Akimoto T; Maebayashi K; Kita M; Mitsuhashi N Anticancer Res; 2008; 28(6B):3859-64. PubMed ID: 19192641 [TBL] [Abstract][Full Text] [Related]
12. Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion. Maehata Y; Hirahashi M; Aishima S; Kishimoto J; Hirohashi S; Yao T; Takashima H; Tsuneyoshi M; Oda Y Hum Pathol; 2011 Apr; 42(4):558-67. PubMed ID: 21239043 [TBL] [Abstract][Full Text] [Related]